Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garsorasib (D-1553) in Advanced Solid Tumors With KRAS G12C Mutation
NCT04585035Phase 2Active, not recruiting
- Sponsor
- InventisBio
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of garsorasib in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by InventisBio. Primary endpoints: Dose-limiting toxicities at 21 days, Number of subjects participants with adverse events at 3 years and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
garsorasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04585035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585035.